import type { Metadata } from "next";
import ClinicalArticleLayout from "@/components/ClinicalArticleLayout";
import Link from "next/link";

export const metadata: Metadata = {
  title: { absolute: "Omega-3 Index Test UK The Cardiovascular Marker Your Blood Panel Doesn't Include | Veridian Clinic" },
  description:
    "The omega-3 index measures EPA and DHA in red blood cell membranes and is one of the strongest predictors of cardiovascular risk available. A high index is linked to roughly 90% lower sudden cardiac death risk. It is not on any standard NHS panel. This GP-authored guide explains what it measures, what the research shows, and how to test privately in the UK.",
  alternates: { canonical: "https://veridianclinic.com/blog/omega-3" },
  openGraph: {
    title: "Omega-3 Index UK The Heart Risk Marker You've Never Had Tested | Veridian Clinic",
    description:
      "A high omega-3 index is linked to roughly 90% lower sudden cardiac death risk vs a low index. It is not on any NHS panel. Here is what the research shows and how to test.",
    url: "https://veridianclinic.com/blog/omega-3",
    type: "article",
  },
  keywords: [
    "omega-3 index test UK",
    "omega-3 blood test UK private",
    "omega-3 index cardiovascular risk",
    "EPA DHA red blood cell UK",
    "omega-3 heart health evidence UK",
    "REDUCE-IT trial omega-3",
    "VITAL trial omega-3 UK",
    "omega-3 index optimal range",
    "fish oil cardiovascular UK",
    "omega-3 deficiency UK",
    "private cardiovascular blood test UK",
    "EPA DHA supplement UK evidence",
  ],
};

const paragraph = { fontSize: ".96rem", color: "var(--sl2)", lineHeight: 1.95 } as const;
const sectionHeading = { fontSize: "2rem", fontWeight: 500, color: "var(--sl)" } as const;
const callout = { padding: "18px 20px", background: "var(--iv)", borderLeft: "3px solid var(--go)" } as const;

const schema = {
  "@context": "https://schema.org",
  "@type": "Article",
  headline: "Omega-3 Index Test UK: The Cardiovascular Marker Your Blood Panel Doesn't Include",
  description:
    "The omega-3 index measures EPA and DHA in red blood cell membranes. A high index is linked to roughly 90% lower sudden cardiac death risk. This GP-authored guide explains what it measures, what the research shows, and how to test in the UK.",
  author: { "@type": "Person", name: "Dr Oluwatosin Taiwo", url: "https://veridianclinic.com" },
  publisher: {
    "@type": "Organization",
    name: "Veridian Clinic",
    url: "https://veridianclinic.com",
    logo: { "@type": "ImageObject", url: "https://veridianclinic.com/og-image.jpg" },
  },
  datePublished: "2026-06-23",
  dateModified: "2026-06-23",
  mainEntityOfPage: { "@type": "WebPage", "@id": "https://veridianclinic.com/blog/omega-3" },
};

const faqSchema = {
  "@context": "https://schema.org",
  "@type": "FAQPage",
  mainEntity: [
    {
      "@type": "Question",
      name: "What is the omega-3 index and how is it measured?",
      acceptedAnswer: {
        "@type": "Answer",
        text: "The omega-3 index is the percentage of EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) in red blood cell membranes, expressed as a percentage of total fatty acids. Because red blood cells have a lifespan of around 120 days, the index reflects long-term omega-3 status rather than recent dietary intake. It is measured from a blood sample and is not included in standard NHS or most private health check panels.",
      },
    },
    {
      "@type": "Question",
      name: "What is a good omega-3 index level?",
      acceptedAnswer: {
        "@type": "Answer",
        text: "An omega-3 index above 8% is generally considered optimal for cardiovascular and brain health. An index below 4% is associated with significantly elevated cardiovascular risk, including sudden cardiac death. US and UK population averages tend to sit in the 4 to 6% range, placing most adults in the suboptimal zone. Japan, with its traditionally high fish consumption, averages around 10%.",
      },
    },
    {
      "@type": "Question",
      name: "How much omega-3 do I need to take to improve my index?",
      acceptedAnswer: {
        "@type": "Answer",
        text: "Most people will move from a low to an optimal omega-3 index with approximately 1.6 to 2 g per day of combined EPA and DHA. This is achievable through oily fish (salmon, mackerel, sardines, anchovies) eaten three or more times per week, or through a quality concentrated fish oil or algae-based supplement. Because starting points vary considerably, testing first is important. A recheck at three to four months confirms whether the dose is working.",
      },
    },
    {
      "@type": "Question",
      name: "Can I get an omega-3 index test privately in the UK?",
      acceptedAnswer: {
        "@type": "Answer",
        text: "Yes. The omega-3 index is included in Veridian Clinic's Cardiovascular Risk Panel (£349) and Longevity Panel (£795), both of which also include ApoB, Lp(a), homocysteine, and other markers not included on standard NHS cardiovascular panels. Results are reviewed by a GP and returned with a written clinical interpretation.",
      },
    },
    {
      "@type": "Question",
      name: "Do omega-3 supplements actually reduce cardiovascular events?",
      acceptedAnswer: {
        "@type": "Answer",
        text: "Two large randomised controlled trials, REDUCE-IT and VITAL, both found meaningful reductions in cardiovascular events in participants taking omega-3 supplementation. REDUCE-IT, which used high-dose prescription EPA in people with elevated triglycerides or established cardiovascular disease, found a 25% reduction in major adverse cardiovascular events. VITAL, which used a standard 1 g per day EPA and DHA supplement in a general adult population, found a significant reduction in cardiovascular death. The evidence for meaningful clinical benefit is among the strongest available for any widely available supplement.",
      },
    },
  ],
};

export default function Omega3Page() {
  return (
    <>
      <script type="application/ld+json" dangerouslySetInnerHTML={{ __html: JSON.stringify(schema) }} />
      <script type="application/ld+json" dangerouslySetInnerHTML={{ __html: JSON.stringify(faqSchema) }} />
      <ClinicalArticleLayout
        eyebrow="Longevity Medicine · Cardiovascular Risk"
        title="The blood marker that predicts your heart risk better than cholesterol gets all the attention"
        intro="Most people have had a cholesterol test. Almost no one has had their omega-3 index measured. A high index of around 8% is linked to roughly 90% lower sudden cardiac death risk compared to a low index of 4%. A low index has been associated with a mortality signal comparable to smoking. It is not on any standard NHS panel. Here is what the evidence says and why it belongs in any serious cardiovascular workup."
        ctas={[
          { href: "/book?tier=cardiovascular-risk", label: "Book Cardiovascular Risk Panel £349, includes omega-3 index →" },
          { href: "/book?tier=longevity-panel", label: "Book Longevity Panel 150+ markers £795", variant: "secondary" },
          { href: "/blood-tests/cardiovascular-risk", label: "View all cardiovascular markers →", variant: "tertiary" },
        ]}
      >
        <div style={callout}>
          <p style={{ fontSize: ".88rem", color: "var(--sl2)", lineHeight: 1.8 }}>
            <strong style={{ color: "var(--fo)" }}>Clinical bottom line:</strong> the omega-3 index is a 120-day average of EPA and DHA in red blood cell membranes, one of the strongest cardiovascular and longevity markers available, yet it is absent from every standard NHS and most private blood panels. A high index is linked to roughly 90% lower sudden cardiac death risk vs a low index. It is both testable and correctable.
          </p>
        </div>

        <h2 className="cg" style={sectionHeading}>What the omega-3 index actually measures</h2>
        <p style={paragraph}>
          Unlike a serum omega-3 test that reflects recent dietary intake, the omega-3 index measures the percentage of EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) that are incorporated into the membranes of red blood cells. Because red blood cells live for approximately 120 days, the index gives a stable, long-term picture of omega-3 status, roughly equivalent to the HbA1c test for blood glucose. It is not influenced by last week's meal.
        </p>
        <p style={paragraph}>
          EPA and DHA are long-chain omega-3 fatty acids that the body cannot efficiently synthesise in meaningful quantities from plant-based precursors. They must come from dietary sources, primarily oily fish, or from supplementation. Once incorporated into cell membranes, they influence membrane fluidity, receptor function, and the production of signalling molecules called eicosanoids and resolvins. Their absence produces membranes that are less fluid and a signalling environment that is less capable of resolving inflammatory processes once they have served their purpose.
        </p>

        <h2 className="cg" style={sectionHeading}>What the research shows about cardiovascular risk</h2>
        <p style={paragraph}>
          The epidemiological evidence on the omega-3 index and cardiovascular outcomes is among the most consistent in preventive cardiology. Studies comparing people with a high omega-3 index of around 8% to those with a low index of around 4% have found approximately 90% lower risk of sudden cardiac death in the high group. Sudden cardiac death, the rapid, unexpected cessation of cardiac function, is the single largest cause of cardiovascular mortality. A tenfold reduction in risk between the high and low omega-3 groups is a striking signal.
        </p>
        <p style={paragraph}>
          A separate analysis of the relationship between omega-3 status and overall mortality produced a finding that has become one of the most cited in preventive medicine: people with a low omega-3 index had an all-cause mortality risk comparable to those of smokers with a high omega-3 index. In other words, low omega-3 status carried a mortality signal similar in magnitude to smoking in that dataset. Across multiple studies, a high versus low omega-3 index is associated with approximately five additional years of life expectancy.
        </p>
        <p style={paragraph}>
          US and UK population averages sit in the 4 to 6% range, placing most adults in the suboptimal zone. Japan, where traditional dietary patterns include substantially higher fish consumption, averages around 10%, and this is frequently cited alongside Japan's consistently high life expectancy in discussions of population-level omega-3 exposure.
        </p>

        <h2 className="cg" style={sectionHeading}>The mechanism: why omega-3 does what it does</h2>
        <p style={paragraph}>
          EPA and DHA are precursors to a class of signalling molecules called resolvins, protectins, and maresins. Unlike conventional anti-inflammatory drugs, which primarily suppress inflammatory signals, these specialised pro-resolving mediators actively terminate inflammatory processes once they have served their biological purpose. This distinction matters clinically: chronic inflammation is not simply too much inflammatory signal. It is often a failure of resolution. Omega-3 fatty acids support the resolution step that conventional anti-inflammatory approaches do not address.
        </p>
        <p style={paragraph}>
          EPA and DHA also maintain the physical fluidity of cell membranes, which affects how efficiently receptors respond to their ligands, how cells signal to each other, and how efficiently platelets aggregate. The cardiovascular relevance is direct: less fluid arterial cell membranes, less efficient nitric oxide signalling, and greater platelet aggregation tendency are all features associated with low omega-3 status. Higher omega-3 status influences all three in a favourable direction.
        </p>

        <h2 className="cg" style={sectionHeading}>Evidence from randomised controlled trials</h2>
        <p style={paragraph}>
          Two large randomised controlled trials have directly examined whether omega-3 supplementation reduces cardiovascular events. REDUCE-IT enrolled approximately 8,000 patients with elevated triglycerides and either established cardiovascular disease or diabetes with risk factors, and randomised them to high-dose prescription EPA (icosapentaenoic acid, 4 g per day) versus placebo. It found a 25% reduction in major adverse cardiovascular events, including a significant reduction in cardiovascular death. VITAL enrolled over 25,000 adults from the general US population in a factorial design testing vitamin D and omega-3. The omega-3 arm (1 g combined EPA and DHA per day) found a significant reduction in cardiovascular death, non-fatal heart attack, and total mortality in analyses of the full trial and subgroups with low baseline fish consumption.
        </p>
        <p style={paragraph}>
          Separately, research on the relationship between omega-3 status and epigenetic ageing found that approximately 1.1 g per day of combined EPA and DHA appears to be a threshold above which a meaningful slowing of biological ageing can be detected. The mechanism here likely involves the anti-inflammatory and membrane effects described above, operating across long time periods rather than on any single acute event.
        </p>

        <div style={callout}>
          <p style={{ fontSize: ".88rem", color: "var(--sl2)", lineHeight: 1.8 }}>
            <strong style={{ color: "var(--fo)" }}>Veridian Clinic note:</strong> the omega-3 index is included in the Cardiovascular Risk Panel (£349) alongside ApoB, Lp(a), homocysteine, hsCRP, small dense LDL, and fasting insulin. It is also part of the Longevity Panel (£795). Both panels include a GP-written interpretation of results against optimal ranges rather than standard lab reference ranges.
          </p>
        </div>

        <h2 className="cg" style={sectionHeading}>How to improve your omega-3 index</h2>
        <p style={paragraph}>
          Most adults will move from the low zone (below 4%) to the optimal zone (above 8%) with approximately 1.6 to 2 g per day of combined EPA and DHA. This can be achieved through regular consumption of oily fish: salmon, mackerel, sardines, anchovies, and herring are the most EPA and DHA-rich options and would need to be eaten approximately three to four times per week for most people to reach these intakes. For those who do not eat oily fish regularly, a concentrated fish oil or algae-based supplement (for vegetarians and vegans) providing at least 1.5 g combined EPA and DHA per day is a reliable alternative.
        </p>
        <p style={paragraph}>
          Because starting points vary considerably between individuals, testing before changing intake is the most efficient approach. Someone with a baseline index of 3% requires a substantially larger dietary or supplemental change than someone at 6%. A recheck at three to four months provides confirmation that the intervention is working and identifies whether the dose needs adjusting. The investment in testing twice is modest compared to the value of knowing that supplementation is producing the intended change.
        </p>

        <h2 className="cg" style={sectionHeading}>Frequently asked questions</h2>
        <div style={{ display: "grid", gap: 18 }}>
          {[
            {
              q: "What is the omega-3 index and how is it measured?",
              a: "The omega-3 index is the percentage of EPA and DHA in red blood cell membranes. Because red blood cells live around 120 days, it reflects long-term omega-3 status, not recent intake. It is measured from a standard blood sample and is not included in NHS or most private health check panels.",
            },
            {
              q: "What is a good omega-3 index?",
              a: "Above 8% is generally considered optimal. Below 4% is associated with significantly elevated cardiovascular risk including sudden cardiac death. UK and US averages sit in the 4 to 6% range, placing most adults in the suboptimal zone.",
            },
            {
              q: "How much omega-3 do I need to improve my index?",
              a: "Most people move from low to optimal with around 1.6 to 2 g per day of combined EPA and DHA, from oily fish three or more times per week or a quality concentrated supplement. Test first, then recheck at three to four months to confirm the dose is working.",
            },
            {
              q: "Do omega-3 supplements actually reduce cardiovascular events?",
              a: "Yes, based on two large randomised controlled trials. REDUCE-IT found a 25% reduction in major adverse cardiovascular events with high-dose prescription EPA. VITAL found a significant reduction in cardiovascular death and non-fatal heart attack with a standard 1 g combined EPA and DHA supplement in a general adult population. The evidence for clinical benefit is among the strongest available for any widely available supplement.",
            },
          ].map(({ q, a }) => (
            <div key={q} style={{ borderTop: "1px solid rgba(44,42,38,.08)", paddingTop: 16 }}>
              <p style={{ fontSize: ".96rem", fontWeight: 600, color: "var(--sl)", marginBottom: 8, lineHeight: 1.5 }}>{q}</p>
              <p style={{ fontSize: ".9rem", color: "var(--sl2)", lineHeight: 1.9 }}>{a}</p>
            </div>
          ))}
        </div>

        <ul className="chk">
          <li>The omega-3 index measures EPA and DHA in red blood cell membranes, reflecting 120-day status, not recent dietary intake.</li>
          <li>A high index (~8%) is linked to roughly 90% lower sudden cardiac death risk vs a low index (~4%).</li>
          <li>Low omega-3 status carries a mortality signal comparable to smoking in some analyses.</li>
          <li>UK and US averages sit in the suboptimal 4 to 6% range.</li>
          <li>Most people reach optimal with 1.6 to 2 g per day of combined EPA and DHA. Testing before and after is the only reliable way to confirm it is working.</li>
          <li>REDUCE-IT and VITAL both found meaningful reductions in cardiovascular events in randomised controlled trials.</li>
        </ul>

        <p style={{ fontSize: ".9rem", color: "var(--sl3)", lineHeight: 1.8, borderTop: "1px solid rgba(0,0,0,.08)", paddingTop: 16 }}>
          Related reading:{" "}
          <Link href="/blog/homocysteine" style={{ color: "var(--go)", textDecoration: "underline" }}>Homocysteine and cardiovascular risk</Link>
          {" · "}
          <Link href="/blog/apob-vs-ldl" style={{ color: "var(--go)", textDecoration: "underline" }}>ApoB vs LDL explained</Link>
          {" · "}
          <Link href="/blog/lipoprotein-a-apob-triglycerides" style={{ color: "var(--go)", textDecoration: "underline" }}>Lp(a), ApoB, and triglycerides</Link>
          {" · "}
          <Link href="/blood-tests/cardiovascular-risk" style={{ color: "var(--go)", textDecoration: "underline" }}>Private Cardiovascular Risk Panel UK</Link>
        </p>
      </ClinicalArticleLayout>
    </>
  );
}
